These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2654329

  • 1. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.
    Hillcoat BL, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R, Olver I, Bishop J, Pearson B, Coorey G.
    J Clin Oncol; 1989 Jun; 7(6):706-9. PubMed ID: 2654329
    [Abstract] [Full Text] [Related]

  • 2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 3. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 4. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Vlamis V, Higgins G, Herr H, Bajorin DF.
    Cancer; 1999 Mar 01; 85(5):1145-50. PubMed ID: 10091800
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chemotherapy of urothelial tract tumors.
    Yagoda A.
    Cancer; 1987 Aug 01; 60(3 Suppl):574-85. PubMed ID: 3297286
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW.
    Cancer; 1999 Oct 01; 86(7):1329-34. PubMed ID: 10506721
    [Abstract] [Full Text] [Related]

  • 13. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 01; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up results of a Pilot Phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer.
    Gohji K, Ono Y, Takenaka A, Nomi M, Okamoto M, Yuen K, Fujii A.
    Jpn J Clin Oncol; 1999 Apr 15; 29(4):204-8. PubMed ID: 10340044
    [Abstract] [Full Text] [Related]

  • 18. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 19. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
    Hashimura T, Okumura K, Akao T, Nakagawa T.
    Hinyokika Kiyo; 1991 Jul 15; 37(7):685-8. PubMed ID: 1927767
    [Abstract] [Full Text] [Related]

  • 20. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G, Milani A, Piva L, Faustini M, Spino E.
    Eur Urol; 1991 Jul 15; 20(2):89-92. PubMed ID: 1752280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.